{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:53:29Z","timestamp":1789872809283,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3472,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1093\/annonc\/mdp483","type":"journal-article","created":{"date-parts":[[2009,10,31]],"date-time":"2009-10-31T00:44:43Z","timestamp":1256949883000},"page":"1168-1172","source":"Crossref","is-referenced-by-count":42,"title":["Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)"],"prefix":"10.1016","volume":"21","author":[{"given":"G.","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Petillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Montella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Del Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bergaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp483_bb0010","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.1999.17.7.2280","article-title":"Thymoma: state of the art","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0015","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13 year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp483_bb0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.coc.0000227481.36109.e7","article-title":"Systemic treatment of malignant thymoma","volume":"29","author":"Giaccone","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.critrevonc.2007.04.005","article-title":"Management of thymomas","volume":"65","author":"Wright","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdp483_bb0035","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.2002.20.2.582","article-title":"Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer","volume":"20","author":"Schilsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/mdg029","article-title":"Biweekly high dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0045","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/cncr.21591","article-title":"Capecitabine combined with gemcitabine (CAPGEM) as first-line treatment in patients with advanced\/metastatic biliary tract carcinoma","volume":"104","author":"Cho","year":"2005","journal-title":"Cancer"},{"issue":"30","key":"10.1093\/annonc\/mdp483_bb0050","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","article-title":"Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial","volume":"23","author":"Knox","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdp483_bb0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/annonc\/mdh065","article-title":"Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study","volume":"15","author":"Stathopoulos","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp483_bb0065","author":"National Cancer Institute","year":"2003","journal-title":"Common terminology criteria for adverse events v3.0"},{"key":"10.1093\/annonc\/mdp483_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation for incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1093\/annonc\/mdp483_bb0075","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10226","article-title":"The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients","volume":"94","author":"Okumura","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdp483_bb0080","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdp483_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0090","article-title":"A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loherer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0095","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.14665","article-title":"Phase II study of imatinib in patients with WHO B3 and C thymomas","volume":"26","author":"Giaccone","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp483_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419392907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419392907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/6\/1168\/446570\/mdp483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:35:41Z","timestamp":1624700141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419392907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0923753419392907"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp483","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}